<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00259974</url>
  </required_header>
  <id_info>
    <org_study_id>P040409</org_study_id>
    <nct_id>NCT00259974</nct_id>
  </id_info>
  <brief_title>RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy</brief_title>
  <official_title>Double-blind Randomized Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henri Mondor University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Marseille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polyneuropathy associated with anti-MAG monoclonal IgM gammopathy is responsive of mainly a
      sensory deficit in predominantly males ,aged 40-70 years. Significantly high serum anti-MAG
      antibodies are linked with demyelinating features of the peripheral nerves.Rituximab, an
      anti-CD 20 monoclonal antibody is a new drug which reduces B-lymphocytes. This study will
      test the safety and efficacy of rituximab in the treatment of patients with anti-MAG
      polyneuropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acting of a polyneuropathy for which there is not any treatment of reference today (see
      supra), a test of double-knowledge versus placebo is justified. Acting of a chronic
      polyneuropathy, the clinical evaluation must be led over one one year period. Acting of a
      sensitive polyneuropathy and the awaited benefit being the IMPROVEMENT OF the CLINICAL SIGNS,
      the principal criterion is a sensitive score in addition validated in chronic sensitive
      polyneuropathies immunodeficiency syndrome.

      The patients answering the criteria of inclusion and none inclusion (see V-2) will be
      randomized in 2 groups: the first group will receive a perfusion IV of rituximab to the
      amount of 375 mg/m2 of body surface, once per week, during 4 weeks (see VII-3); the second
      group will receive 4 perfusions IV of placebo according to same methods'. The evaluation (see
      VI-1) will be carried out at the time of the randomization, then repeated in 3 months, 6
      months, 9 months and 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>INCAT sensory score at 1 year</measure>
    <time_frame>during de study</time_frame>
    <description>INCAT sensory score at 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional scales, MRC score</measure>
    <time_frame>during the study</time_frame>
    <description>Functional scales, MRC score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SF 36)</measure>
    <time_frame>during the study</time_frame>
    <description>Quality of life (SF 36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lymphocytes count, IgM level, anti-MAG antibody titers</measure>
    <time_frame>during the study</time_frame>
    <description>Serum lymphocytes count, IgM level, anti-MAG antibody titers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrophysiological parameters</measure>
    <time_frame>during the study</time_frame>
    <description>Electrophysiological parameters</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Polyneuropathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IgM monoclonal gammopathy

          -  Anti-MAG antibody titers &gt; 1.1000 BTU (ELISA)

          -  Worsening polyneuropathy with INCAT score &gt; 4

          -  Informed consent

        Exclusion Criteria:

          -  Severe comorbidity

          -  Other concurrent causes of polyneuropathy

          -  Concurrent immunosuppressive therapies (wash-out &gt; 3 months)

          -  Previous treatment with rituximab

          -  Lymphoproliferative disease indicating other immunosuppressive treatment

          -  Unability to follow-up

          -  Previous documented side-effects with components involved in the tested drug

          -  White cell count &lt; 1500/mm3 or platelet count &lt; 75.000/mm3

          -  Patient under law
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>82 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc LEGER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié-Salpétrière, Consultation de Pathologie Neuromusculaire, Bâtiment Babinski</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Léger JM. A review of the medical management of chronic inflammatory demyelinating polyradiculoneuropathy. Expert Opin Pharmacother. 2005 Apr;6(4):569-82. Review.</citation>
    <PMID>15934883</PMID>
  </reference>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2005</study_first_submitted>
  <study_first_submitted_qc>November 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2005</study_first_posted>
  <last_update_submitted>May 5, 2011</last_update_submitted>
  <last_update_submitted_qc>May 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Isabelle BRINDEL</name_title>
    <organization>Department of Clinical Research of developpement</organization>
  </responsible_party>
  <keyword>Anti-MAG monoclonal gammopathy</keyword>
  <keyword>Polyneuropathy</keyword>
  <keyword>Rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Paraproteinemias</mesh_term>
    <mesh_term>Monoclonal Gammopathy of Undetermined Significance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

